Podcasts about Teva

Programa de l'Àrea de Polítiques d'Igualtat, coordinat per Olga Alonso, en què s'explicaran les actuacions que es duen a terme a la Seu d'Urgell i l'Alt Urgell per a la promoció de la igualtat d'oportunitats podcast recorded with enacast.com

This is Derek Miller, Speaking on Business. Utah's life sciences industry is a key driver of our state's economy, and BioUtah serves as its dedicated trade association — working to ensure the state remains a leader in life sciences innovation. President and CEO, Kelvyn Cullimore, joins us with more. Kelvyn Cullimore: As one of the fastest-growing biotech hubs in the nation, Utah's life sciences industry generates over 22 billion dollars in GDP, 182,000 jobs and wages at nearly 50 percent higher than the state average. This industry is comprised of medical device and diagnostic manufacturers, pharmaceutical companies, medical labs, and research facilities, whose products touch millions of patients each year and help fuel the Utah economy. BioUtah members include medical device manufacturers like Merit Medical, BD, Stryker and Fresenius; medical laboratories like ARUP and Nelson Labs; and pharmaceutical developers Teva, Denali, and Halia Therapeutics, among many others. Utah punches well above its weight in bringing innovative medical technologies to patients worldwide, such as brain and computer interface technology from Blackrock Neurotech, innovative heart valve replacement systems by Edwards Lifesciences, AI for enhanced drug discovery by Recursion, and Nusano's radioisotope technology, and so much more. Derek Miller: BioUtah is on a mission to build awareness and advance Utah's innovative, patient-focused life sciences industry. Through their work, they're making a real difference in the lives of Utahns. Learn more at BioUtah.org today. I'm Derek Miller, with the Salt Lake Chamber, Speaking on Business. Originally aired: 5/13/25

If you're looking for a podcast episode that moves beyond surface-level talk and gets into the heart of why environmental justice matters, this episode of The Unfolding: Presented by The Loveland Foundation Podcast is worth your time.Host Rachel Keener sits down with Leah Thomas — known to many as Green Girl — an environmental activist and the voice behind the term intersectional environmentalist. Leah opens up about her path from growing up in Missouri to becoming a leading voice in the sustainability space, tracing how something as personal as her natural hair journey first got her thinking about what sustainability really means.But this isn't just about recycling or climate stats. Leah draws powerful connections between environmental issues and social and racial justice, explaining why true sustainability has to include communities that have long been left out of the conversation — especially Black communities. She shares how she builds spaces of care and creativity, like her Crafting Club, where people can come together, learn to make everyday items, and support one another.This episode doesn't fall into the trap of focusing only on crisis and catastrophe. Instead, Leah talks about the joy and healing that can come from reconnecting with the earth, caring for our mental health, and building community-based solutions. It's a conversation that offers hope without ignoring hard truths — and a reminder that the future can look different if we all understand and honor our connection to the planet.If you want to feel inspired and grounded at the same time, give this episode a listen.More about Leah Thomas @GreenGirlLeah:Leah is a celebrated environmentalist based in Los Angeles, CA. Coining the term ‘eco-communicator' to describe her style of environmental activism. Leah uses her passion for writing and creativity to explore and advocate for the critical yet often overlooked relationship between social justice and environmentalism. Her work includes consulting with brands like Apple and TAZO, projects with Meta, KEEN, TEVA, Indie Best Selling Book The Intersectional Environmentalist, and working on the Communications team at Patagonia HQ. Learn more about Leah Thomas HERE.–The Unfolding: Presented by The Loveland Foundation podcast is an additional resource not only to the public but also to our therapy fund cohort members. The Loveland Foundation therapy fund and resources are only made possible through support from our community. At The Loveland Foundation, we are committed to showing up for communities of color in unique and powerful ways, with a particular focus on Black women and girls. Our resources and initiatives are collaborative and they prioritize opportunity, access, validation, and healing. Since our founding, the Therapy Fund has provided financial support for therapy to over 13,000 Black women, girls, and non-binary individuals across the country.Links:Donate to Camp Loveland: https://thelovelandfoundation.org/donateSupport the show: https://give.thelovelandfoundation.org/give/436656/#!/donation/checkoutFollow Leah on Instagram: https://www.instagram.com/greengirlleah/Follow The Loveland Foundation on Instagram: https://www.instagram.com/thelovelandfoundation/Visit the website: https://thelovelandfoundation.org/Support the show

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

podcast recorded with enacast.com

Is the rally overdone? HSBC says yes. We'll speak to the company's chief of multi-asset strategy. Plus, the pharma is facing lots of headwinds on several fronts. We'll speak with the CEO of Teva about how the industry can respond and get through it. And, an interview with the Education Secretary, Linda McMahon about the administration's battle with Harvard.

podcast recorded with enacast.com

podcast recorded with enacast.com

¿El futuro de LinkedIn pasa por el vídeo? ¿TikTok es ya también para mayores? ¿Listo para surfear la ola tecnológica? 🌊 En este emocionante viaje al futuro desde Zaragoza, exploramos cómo la tecnología está transformando nuestras vidas y trabajos. Descubre todo sobre "The Wave," un evento único que reunió a más de 11,000 personas para conectar innovación, humanidad y emprendimiento. Con entrevistas exclusivas a líderes como Ángel Sáenz de LinkedIn y Teva Lorenzo de TikTok, reflexionamos sobre la importancia de la realidad extendida, la inteligencia artificial y el impacto de las redes sociales. Además, conoce cómo Aragón está liderando la revolución tecnológica en España. ¡No te quedes atrás, súmate a esta ola de cambio y evolución! Volvo presenta Pioneros For Life, un programa de Juanma Ortega producido por Adio.FM

Programa de l'Àrea de Polítiques d'Igualtat, coordinat per Olga Alonso, en què s'explicaran les actuacions que es duen a terme a la Seu d'Urgell i l'Alt Urgell per a la promoció de la igualtat d'oportunitats podcast recorded with enacast.com

En un món hostil i oblidat, en un desert de pols i desolació, on el passat i el futur s'entrellacen en un desafiament existencial. Els seus ulls, carregats amb la pesada càrrega de la solitud, escodrinyen l'horitzó amb cautela, sabent que la única certesa és la que ressona a la seva ment, preguntant-se en silenci: podcast recorded with enacast.com

Three guests on this super-sized episode! Senior OLB Tevarua Tafiti takes us inside the locker room as Stanford spring football continues. Stanford Men's Gymnastics Head Coach Thom Glielmi previews this week's NCAA Championships as the Cardinal aim for its sixth straight national title. And Associate Athletic Director, Facilities & Housing Dan Levine tells how Stanford Stadium became a softball facility this season and what it took to get ready for this week's Big Swing!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

¿El futuro de LinkedIn pasa por el vídeo? ¿TikTok es ya también para mayores? ¿Listo para surfear la ola tecnológica? 🌊 En este emocionante viaje al futuro desde Zaragoza, exploramos cómo la tecnología está transformando nuestras vidas y trabajos. Descubre todo sobre "The Wave," un evento único que reunió a más de 11,000 personas para conectar innovación, humanidad y emprendimiento. Con entrevistas exclusivas a líderes como Ángel Sáenz de LinkedIn y Teva Lorenzo de TikTok, reflexionamos sobre la importancia de la realidad extendida, la inteligencia artificial y el impacto de las redes sociales. Además, conoce cómo Aragón está liderando la revolución tecnológica en España. ¡No te quedes atrás, súmate a esta ola de cambio y evolución! Volvo presenta Pioneros For Life, un programa de Juanma Ortega producido por Adio.FM

This Day in Legal History: Patent Act of 1790On April 10, 1790, the United States passed its first patent law, the Patent Act of 1790, laying the groundwork for a legal framework that would protect inventors and promote innovation. This early legislation granted inventors the exclusive right to their discoveries for a period of 14 years, provided the invention was deemed "useful and important." It was signed into law by President George Washington and represented one of the earliest legal efforts by the new republic to encourage economic growth through technological advancement. The law established a board composed of the Secretary of State, the Secretary of War, and the Attorney General, who were tasked with reviewing patent applications and deciding whether to approve them.Notably, the law gave the federal government broad discretion over what could be patented and required that a patent be granted only if the invention was new and useful. The first U.S. patent under this act was issued on July 31, 1790, to Samuel Hopkins for a process of making potash, a key industrial chemical. Although modest in scope, the law was revolutionary in its recognition of intellectual property as a public good worth safeguarding. It helped move the United States toward a more structured innovation economy, setting a precedent that influenced global norms on patent protection.The 1790 law was replaced just three years later by the Patent Act of 1793, which shifted the review process to a more administrative function, but the foundational principle—that inventors should have exclusive rights to their creations—remained intact. This early commitment to fostering invention through legal means helped spur the rapid technological growth that would define American industry in the 19th century and beyond. The act exemplified how the law could be used to incentivize creativity and economic development at a national scale.Bristol Myers Squibb successfully got a proposed class action lawsuit dismissed that had accused it of using fraudulent tactics to maintain a monopoly over its cancer drug, Pomalyst. The suit, led by Blue Cross Blue Shield of Louisiana, claimed that Bristol Myers and its subsidiary Celgene illegally secured patents and filed sham lawsuits to delay the entry of generic versions of Pomalyst, which is used to treat multiple myeloma. However, U.S. District Judge Edgardo Ramos ruled that the plaintiffs failed to prove that any of the six patents were obtained through fraud. He also found no evidence that the nine lawsuits Celgene filed between 2017 and 2020 against generic manufacturers like Teva and Mylan were baseless or intended to secure fraudulent settlements.The plaintiffs alleged that they had been overpaying for the drug since October 2020, the point at which generics could have entered the market if not for the alleged conduct. Pomalyst brought in $3.55 billion in sales in 2024, accounting for more than 7% of Bristol Myers' revenue. Celgene originally developed the drug, and Bristol Myers acquired the company in 2019. The case was heard in the U.S. District Court for the Southern District of New York.Bristol Myers wins dismissal of lawsuit alleging Pomalyst monopoly | ReutersThe Trump administration has frozen over $1 billion in federal funding for Cornell University and $790 million for Northwestern University amid investigations into alleged civil rights violations. The freeze affects grants and contracts from several federal agencies, including health, education, agriculture, and defense. This move is part of a broader crackdown targeting universities over pro-Palestinian campus protests, diversity programs, and transgender policies. The administration previously warned 60 universities, including Cornell and Northwestern, about potential enforcement if they failed to address what it labeled as antisemitism.Cornell confirmed it received “stop work” orders from the defense department affecting research projects but said it hasn't been formally notified of the total funding freeze. Northwestern similarly acknowledged awareness of media reports but stated it hadn't received official notice. The university emphasized the freeze could endanger critical research, including projects on cybersecurity, pacemakers, and Alzheimer's treatment.This action follows similar measures taken against Harvard, Princeton, Columbia, and the University of Pennsylvania. Columbia, which lost $400 million in funding, later agreed to administrative changes in exchange for potential reinstatement. Federal agents have also begun detaining and deporting some foreign student protesters, revoking visas in the process. Critics, including human rights groups, have voiced concerns over free speech, academic freedom, Islamophobia, and anti-Arab discrimination amid the escalating response to pro-Palestinian activism on campuses.US freezes funding for Cornell, Northwestern University in latest crackdownPresident Trump has issued a new executive order aimed at blocking state-level climate policies that seek to reduce fossil fuel use and limit carbon emissions. The directive instructs the U.S. attorney general to identify and challenge state laws related to climate change, environmental justice, ESG (environmental, social, and governance) standards, and carbon regulation. The move aligns with Trump's broader agenda to boost domestic fossil fuel production and roll back Democratic-led environmental initiatives.The order specifically targets policies in states like New York, Vermont, and California, including financial penalties on fossil fuel companies, California's cap-and-trade system, and climate-related lawsuits brought by state governments. Trump described these measures as ideologically driven and harmful to national energy and economic security.Governors Kathy Hochul (NY) and Michelle Lujan Grisham (NM), co-chairs of the U.S. Climate Alliance, condemned the order, asserting states' rights to enact environmental protections. They reaffirmed their commitment to clean energy and climate resilience. The American Petroleum Institute supported Trump's move, framing it as a defense against unconstitutional state actions that burden oil and gas companies.Trump issues order to block state climate change policies | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Send us a textJoin us for this episode as we dive a little deeper into the Imperfect Tense in Catalan. We use this tense to talk about recurring actions in the past or to describe things in the past.Tune in to find out more and specifically how to talk about what our school days were like!Let us know how you found the episode/how you are finding the Pod in general or anything else. We love getting to know our listeners!Support the showGroup Lessons starting 7th April 2025: Group ProgrammesBeginners Course: Catalan for Beginners CoursePatreon: The Lazy Linguist Buy us a coffee: Buy me a Coffee Instagram: @lazylinguistcatalan Facebook: The Lazy Linguist PodcastChristina offers private lessons - enquire through a DM on socials or through the link: Private lessons

En un món hostil i oblidat, en un desert de pols i desolació, on el passat i el futur s'entrellacen en un desafiament existencial. Els seus ulls, carregats amb la pesada càrrega de la solitud, escodrinyen l'horitzó amb cautela, sabent que la única certesa és la que ressona a la seva ment, preguntant-se en silenci: podcast recorded with enacast.com

No tot el pop

Al "Revoluci

„Atenție, cade democrația!” este titlul unui raport lansat de Fundația Konrad Adenauer din România, o culegere de articole despre cum poate fi combătut, pe termen lung, declinul democrației de la noi. Care sînt primele semnale că democrația începe să se clatine? Este democrația un sistem fragil sau puternic? Ce se poate face pentru combaterea declinului democrației – ce se poate face la nivelul autorităților statului și la nivelul societății? L-am întrebat pe Mihai Marc, unul dintre coordonatorii raportului.În ultima ediție a Indexului democrației la nivel mondial, realizat de revista „The Economist”, România a fost clasată drept „regim hibrid“. Retrogradarea reflectă o prăbușire semnificativă a indicatorilor democratici. E unul dintre cele mai abrupte declinuri la nivel global - o coborîre cu 12 poziții în clasament. Dincolo de acest accident de parcurs, dincolo de anularea alegerilor și de situația de interimat a președintelui, avem o democrație funcțională?Mihai Marc: „Fără să intru în scandalul şi şocul de anul trecut, eu cred că a funcţionat democraţia. Problema noastră este că încrederea populaţiei este extrem de scăzută. Şi de aici ne-a şi plecat gîndul pentru publicaţie. Cîtă vreme nu alimentăm permanent şi nu reconstruim acest fundament, această bază pe care funcţionăm toţi şi unde avem libertăţile cetăţeneşti şi individuale, democraţia cade exact cum cade şi tencuiala de pe casă, încet, încet. (...) Am zis iniţial că sîntem poate prea alarmişti cu Atenţie, cade democraţia!, dar cînd am văzut raportul The Economist, am zis că, iată, e mai multă lume care spune acelaşi lucru. Cred că sîntem suficient de critici dar şi constructivi în acest raport, aducem şi soluţii. Avem cîte patru, cinci pagini pentru fiecare articol, unde prezentăm problemele, dar e important să venim şi cu soluţii.”Cum restabilim încrederea cetăţenilor în sistemul democratic?Mihai Marc: „Vorbind cu ei, explicîndu-le ce facem, dînd socoteală pentru banii publici, făcînd asta constant, regulat, cu respect, sinceritate şi transparenţă. E un proces extrem de lung, e un maraton. Din păcate, cred că instituţiile publice şi partidele nu mai pleacă de la 0, pleacă de undeva de la –2 şi au foarte multă muncă de convingere de făcut, iar asta durează. Dar este un proces sănătos şi necesar, cu atît mai mult cu cît influenţele din Rusia, războiul din faţa uşii noastre sînt semne clare de vulnerabilitate, nu mai merge cu faimosul merge şi-aşa. Nu mai merge şi-aşa. Timpul în care am stat într-o oarecare băltire s-a cam terminat.”Apasă PLAY pentru a asculta interviul integral! O emisiune de Adela Greceanu și Matei Martin Un produs Radio România Cultural 

En un món hostil i oblidat, en un desert de pols i desolació, on el passat i el futur s'entrellacen en un desafiament existencial. Els seus ulls, carregats amb la pesada càrrega de la solitud, escodrinyen l'horitzó amb cautela, sabent que la única certesa és la que ressona a la seva ment, preguntant-se en silenci: podcast recorded with enacast.com

In this CME podcast, Dr. Andrew Cutler and Dr. Roger McIntyre discuss the use of potentially unsafe drug combinations in patients with treatment-resistant psychiatric conditions. They review situations where complex medication regimens may be necessary and how clinicians may proceed in these instances. By addressing these topics, the podcast offers guidance on balancing the potential benefits of combination therapies with the risks associated with polypharmacy in psychiatric care.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Identify common potentially unsafe drug combinations that may be considered in treatment-resistant cases Evaluate the risks and benefits of prescribing potentially unsafe drug combinations for treatment-resistant patients, considering factors such as efficacy, adverse effects, and patient-specific characteristics Develop strategies to monitor and manage patients prescribed potentially unsafe drug combinations Accreditation: In support of improving patient care, this activity has been planned and implemented by HMP Education and Neuroscience Education Institute (NEI). HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with synchronized audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour. Released: March 26, 2025*   Expiration: March 25, 2028 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD25-01 Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ HMP Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse: ANCC contact hours This continuing nursing education activity awards 1.00 contact hour. Provider approved by the California Board of Registered Nursing, Provider #18006 for 1.00 contact hour. Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.00 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI and HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and are unable to report your claimed credit after this 60-day period. Ensure your profile includes your DOB and NABP ID. Physician Associate/Assistant: AAPA Category 1 CME credits HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit. Approval is valid until March 25, 2028. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. This activity awards 1.00 CE Credit. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, HMP Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.00 general continuing education credit. Non-Physician Member of the Healthcare Team: Certificate of Participation HMP Education awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, and cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI and HMP Education take responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, New York Chief Medical Officer, Neuroscience Education Institute, Malvern, Pennsylvania Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, Ontario, Canada CEO, Braxia Scientific Corp, Toronto, ON, Canada Grant/Research: Canadian Institutes of Health Research, China National Natural Research Foundation, Global Alliance for Chronic Diseases, Milken Institute Consultant/Advisor: Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris The remaining Planning Committee members, Content Editors, Peer Reviewer, NEI and HMP planners/staff have no financial relationships to disclose. NEI and HMP Education planners and staff include Gabriela Alarcón, PhD, Ali Holladay, Andrea Zimmerman, EdD, CHCP, Brielle Calleo, and Steven S. Simring, MD, MPH. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported solely by the provider, NEI.

South East Technological University (SETU), in collaboration with the Engineering the South East Cluster (ESE) and its automation sub-group, is proud to announce the launch of an innovative multi-company automation scholarship designed to retain top engineering talent within the region. A recent Higher Education Authority (HEA) report revealed that 62% of engineering students from the southeast region leave to study elsewhere, with a significant impact on the local workforce. In response to this, SETU's Autom8 scholarship initiative aims to attract and support students pursuing automation and robotics engineering careers, while addressing the region's growing demand for skilled professionals in industry. Speaking at the launch of the scholarship, Stephen Rooney, Cluster Manager, Engineering the South East, SETU, said, "The Autom8 scholarship is set to enhance local career opportunities, reduce brain drain, and strengthen industry-academic collaboration. It aligns with SETU's mission to support regional economic growth by fostering a pipeline of skilled graduates who can drive technological innovation in the southeast." The Autom8 scholarship brings together a group of leading manufacturing and automation companies to offer students financial support, industry experience, and professional mentorship throughout their undergraduate studies at SETU. Companies partnering with SETU on this initiative include MSD Ireland, Integer, Teva, Sanofi, and Bausch + Lomb. Edmond Connolly, Manager, South East Regional Skills Forum, said "SETU and Engineering the South East encourage interested second-level students to apply and seize this opportunity to advance their careers in automation engineering within a thriving local industry." The scholarship is open to students enrolling on SETU's Bachelor of Engineering (B.Eng.) in Automation Engineering (Waterford campus) and the Bachelor of Robotics and Automated Systems (Carlow campus) Each participating company will provide a €2,000 annual contribution towards a student's educational expenses, along with access to paid summer work, a third-year industrial placement, and a dedicated industry mentor. More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us on Twitter, LinkedIn, Facebook, Instagram, TikTok and Snapchat.

En un món hostil i oblidat, en un desert de pols i desolació, on el passat i el futur s'entrellacen en un desafiament existencial. Els seus ulls, carregats amb la pesada càrrega de la solitud, escodrinyen l'horitzó amb cautela, sabent que la única certesa és la que ressona a la seva ment, preguntant-se en silenci: podcast recorded with enacast.com

On today's podcast, we were joined by so many incredible people including Ria Hall, who stood at Te Matatini and our Flava Fugitive winner Teva live from Vegas. Plus, Monday G Up got a bit out of control and we hope Azura isn't cancelled. For more, follow our socials: Instagram Facebook TikTokSee omnystudio.com/listener for privacy information.

On this week's episode, Brad Loncar, Daphne Zohar, Josh Schimmer, Yaron Werber and Michael Preminger kick off the show with Vertex's much anticipated Phase 2 study results, highlighting the modest treatment effect and high placebo response. The group also comments on overly positive spin on data and the importance of credibility in interpreting data. The conversation turns to Novo Nordisk's weight loss data and the market's negative reaction with stock down 20%. The group also discusses Roche's termination of its hemophilia gene therapy program, and Teva's TL1A data showing promise in inflammatory bowel disease. Turning to market sentiment, the group comments on Wall Street's high expectations for new data and the resulting volatility in the market. The hosts also touch on the impact of Chinese biotech investments, potential PBM reforms, Regeneron's high-dose ILEA trials, upcoming auction of Mitsubishi pharma unit, and more. This episode aired on December 20, 2024.

You cannot get a patent if your invention is obvious. This can be tricky to determine for biotech and pharmaceutical patents. There are competing standards for how this is determined. One is the "reasonable expectation of success" standard, which is a lower threshold than the "predictable results" standard. The Supreme Court refused to hear a case that would have settled this, so we're left with the Federal Circuit's ruling in the case of Vanda Pharmaceuticals vs. Teva Pharmaceuticals. Listen to this episode to learn how these tests can give different results for patentability and what it means for the future biotech and drug patents!

Creatives often feel tension between honoring what a brand wants and respecting the authentic story of a person or community. How can you do both?   Sabrina Claros is a photographer, videographer, and creative director based in LA, creating stories at the intersection of adventure, environmentalism, and outdoor equity. Her work aims to create change and inspire more people to connect with the outdoors and feel called to protect our natural resources, while reducing barriers to who has access in outdoor spaces.   Sabrina has worked with brands such as Teva, Tough Cutie, Bedrock Sandals, and many others. Her media work is largely informed by a background in social work, and continues to be grounded in grassroots community work.   We chat about: Sabrina's move from social work to outdoor industry media How essential community is to staying resilient when facing challenges The challenges of outsiders sharing the stories of underrepresented communities Balancing authentic storytelling with a brand's needs Cold pitching and specificity The need for a creative network to amplify diverse voices Keeping the creative process fulfilling even when it's for work   Connect with Sabrina: www.sabrinaclaros.com www.instagram.com/sabrinaclarosphotography   Connect with Justine: Website: https://www.justawildthought.com Instagram: https://www.instagram.com/justawildthought    Was this episode helpful? Screenshot this and tell a friend to go to justawildthought.com/podcast! Please rate and review Creatives in the Wild on Apple Podcasts, Spotify, or wherever you listen.

Volem reivindicar un instrument modest que sempre s'ha relacionat de manera injusta amb les festes de Nadal i la tuna universit

As the AI race heats up, could it be a “watershed” moment for the software stocks? We debate and give you some names to buy. Plus, why the new administration could be bullish for small caps. And, Teva's CEO discusses the company's outlook, transition and the future of drug pricing negotiations. 

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world.AbbVie has entered into a collaboration with Neomorph worth up to $1.64 billion for molecular glue. Neomorph, a protein degradation-focused company, has secured its third big pharma deal in less than a year. In other news, Vigil Neuroscience's Alzheimer's treatment has shown early promise in reducing Trem2 levels. Vanda lost a confidentiality complaint against the FDA. Biogen is trimming its research workforce while their higher-dose SMA drug is under regulatory review. Samsung Biologics has secured a $1.4 billion European contract. Teva's Copaxone receives a boxed warning from the FDA. Tris Pharma has recorded a late-stage win for a non-opioid painkiller. J&J predicts that deals are likely to shrink after their $14.6 billion acquisition of Intra-Cellular. In the biopharma industry, there are questions surrounding policies under the new administration. Gilead executives have started over with a new spinoff after almost 5 years into a $5 billion partnership with Galapagos.

Teva Pharmaceuticals CEO Richard Francis reflects on company performance in 2024, drug pricing, getting more drugs to market and supply shortages of the drug Adderall. He speaks to Bloomberg's Katie Griefeld from the JPMorgan Healthcare Conference.See omnystudio.com/listener for privacy information.

Hier geht's zu unserem YouTube-Kanal und dem vollen Interview. https://www.youtube.com/@ohneaktienwirdschwer-podcast/videos Erfahre hier mehr über unseren Partner Scalable Capital - dem Broker mit Flatrate und Zinsen. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. KI-Hype ist weg. Quantencomputer-Hype ist da. Bitcoin-Hype bleibt. Ansonsten war Teva wie Bayer und ist jetzt High-Performer. Trump versenkt paar Gesundheits-Aktien und Thyssenkrupp Nucera + Pfizer haben solide Zahlen. Skechers (WKN: 922814) wurde nie so gehyped wie On, Hoka oder Lululemon. Ein High-Performer war die Aktie trotzdem. Wie geht's jetzt weiter? 120 Ironmans in 120 Tagen. Unfassbar. Jonas Deichmann hat's geschafft. Jonas ist aber nicht nur Extremsportler, sondern auch Investor. Wie investiert er und was können Investoren von ihm über den Umgang mit Risiko lernen? Das erzählt er heute im Podcast. Diesen Podcast vom 18.12.2024, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Teva Pharmaceutical (TEVA) closed at its highest stock price of the year after it and Sanofi (SNY) say their IBD treatment had higher remission in trial. George Tsilis looks at how the development can be the first step in a turnaround for the company. ======== Schwab Network ======== Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185 Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7 Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore Watch on DistroTV - https://www.distro.tv/live/schwab-network/ Follow us on X – https://twitter.com/schwabnetwork Follow us on Facebook – https://www.facebook.com/schwabnetwork Follow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Surrogate decision making has some issues.  Surrogates often either don't know what patients would want, or think they know but are wrong, or make choices that align with their own preferences rather than the patients.  After making decisions, many surrogates experience regret, PTSD, and depressive symptoms.  Can we do better? Or, to phrase the question for 2024, “Can AI do better?” Follow that path and you arrive at a potentially terrifying scenario: using AI for surrogate decision making.  What?!?  When Teva Brender and Brian Block first approached me about writing a thought piece about this idea, my initial response was, “Hell no.”  You may be thinking the same.  But…stay with us here…might AI help to address some of the major issues present in surrogate decision making? Or does it raise more issues than it solves? Today we talk with Teva, Dave Wendler, and Jenny Blumenthal-Barby about: Current clinical and ethical issues with surrogate decision making The Patient Preferences Predictor (developed by Dave Wendler) or Personalized Patient Preferences Predictor (updated idea by Brian Earp) and commentary by Jenny Using AI to comb through prior recorded clinical conversations with patients to play back pertinent discussions; to predict functional outcomes; and to predict patient preferences based on prior spending patterns, emails, and social media posts (Teva's thought piece) A whole host of ethical issues raised by these ideas including the black box nature, the motivations of private AI algorithms run by for profit healthcare systems, turning an “is” into an “ought”, defaults and nudges, and privacy. I'll end this intro with a quote from Deb Grady in an editor's commentary to our thought piece in JAMA Internal Medicine about this topic: “Voice technology that creates a searchable database of patients' every encounter with a health care professional? Using data from wearable devices, internet searches, and purchasing history? Algorithms using millions of direct observations of a person's behavior to provide an authentic portrait of the way a person lived? Yikes! The authors discuss the practical, ethical, and accuracy issues related to this scenario. We published this Viewpoint because it is very interesting, somewhat scary, and probably inevitable.” -@alexsmithmd.bsky.social  

Dave Powers serves as President & CEO of Deckers Brands, a global footwear and apparel company based in Santa Barbara, Calif. His current role includes prioritizing strategic initiatives and investments to expand the global distribution footprint of Deckers Brands, while also ensuring consumers have a seamless experience when engaging directly with each channel or brand. He focuses on long-term growth and Omni Channel strategies for the company's five high-performing brands: UGG®, Teva®, Sanuk®, HOKA One One® and Koolaburra®. Since 2012, Dave has served in various roles at Deckers Brands, including spearheading growth initiatives for the company's brand portfolio as President of Brands and leading direct-to-consumer strategies as President of Direct-to-Consumer. Dave is passionate about consumer-led insight and innovation as well as doing great in business and doing good for people and the planet. His passion for innovation as well as improvement led by consumer insight has resulted in gains in operating margin and revenue. Dave also remains committed to sustainability as well as making a positive societal impact and leading a strong company culture. Under his leadership as President & CEO since 2016, Deckers Brands has received accolades for stellar financial performance and sustainability efforts. In 2019, Deckers was selected by Investor's Business Daily® as one of the 50 Best ESG Companies: A List of Today's Top Stocks For Environmental, Social and Governance Values. The company was also recognized by Footwear News as 2020 Company of the Year for its financial performance and commitment to diversity, equity and inclusion as well as significant charitable giving for COVID-19 relief.  In 2020, Dave was named a 2020 Businessperson of the Year by Fortune, ranking number 13 on their list of top executives. Dave has over twenty years of experience in merchandising, concept development and leadership of global retail operations at some of the industry's top brands. Prior to joining Deckers Brands, he held executive leadership roles at Converse, including four years as Vice President of Global Direct-to-Consumer where he successfully guided the expansion of the brand globally, and Timberland, where he led worldwide retail merchandising, marketing, visual and store design as well as the creation of a sustainable line of footwear and apparel. A native of New Hampshire, Dave graduated Cum Laude from Northeastern University with a bachelor's degree in marketing. Now residing in Santa Barbara, Calif., he enjoys spending time outdoors with his wife and two sons.

Evaluation and Credit:  https://www.surveymonkey.com/r/Medchat73 Target Audience   This activity is targeted toward primary care physicians and advanced providers.  Statement of Need The relationship between female hormones and migraines is complex and primary care providers may not be aware of the latest research regarding the role of hormonal changes during different life stages (e.g., menarche, pregnancy, and menopause) and their impact on migraine patterns or the latest management guidelines. By addressing these needs, the podcast will equip clinicians with the tools to better diagnose, treat, and prevent hormonal migraines, ultimately improving patient care and outcomes. Objectives At the conclusion of this offering, the participant will be able to:  Review the diagnostic criteria of migraines and characteristics of hormonal migraines. Discuss treatment and prevention strategies for hormonal migraines, including during pregnancy. Describe the role hormones in the treatment of migraines.   ModeratorBrian Plato, D.O., FAHS Neurologist Medical Director Headache Medicine, Neurology Norton Neuroscience Institute Norton Healthcare Louisville, Kentucky  SpeakersKris Barnsfather, M.D. Obstetrician Gynecologist Women's Care Physicians of Louisville Norton Healthcare Louisville, Kentucky Christopher Rhyne, M.D. Neurologist Headache Medicine, Neurology Norton Neuroscience Institute Norton Healthcare Louisville, Kentucky Moderator and Planner Disclosures  The planners and moderator of this activity do not have any relevant financial relationships with ineligible companies to disclose.   Speaker DisclosureThe speaker Kris Barnsfather, M.D. does not have any relevant financial relationships with ineligible companies to disclose.  The speaker Christopher Rhynes, M.D., has relevant financial relationships with ineligible companies Lundbeck and Abbvie as a speaker/consultant. Relevant financial relationships with ineligible companies Pfizer and Lilly as a speaker/consultant; and Amgen, Teva and Impel as a speaker have ended. All relevant financial relationships have been mitigated. Commercial Support  There was no commercial support for this activity.  Physician Credits Accreditation Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians. Designation Norton Healthcare designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For more information about continuing medical education, please send an email to cme@nortonhealthcare.org.  Nursing CreditsNorton Healthcare Institute for Education and Development is approved with distinction as a provider of nursing continuing professional development by the South Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. This continuing professional development activity has been approved for .75 contact hours. In order for nursing participants to obtain credits, they must claim attendance by attesting to the number of hours in attendance.   For more information related to nursing credits, contact Sally Sturgeon, DNP, RN, SANE-A, AFN-BC at (502) 446-5889 or sally.sturgeon@nortonhealthcare.org. Resources for Additional Study/References Migraine: navigating the hormonal minefield https://pubmed.ncbi.nlm.nih.gov/31753858/ Role of Estrogens in Menstrual Migraine https://pubmed.ncbi.nlm.nih.gov/35456034/ Date of Original Release | Dec. 2024; Information is current as of the time of recording. Course Termination Date | Dec. 2027 Contact Information | Center for Continuing Medical Education; (502) 446-5955 or cme@nortonhealthcare.org Norton Healthcare, a not for profit health care system, is a leader in serving adult and pediatric patients throughout Greater Louisville, Southern Indiana, the commonwealth of Kentucky and beyond. More information about Norton Healthcare is available at NortonHealthcare.com.

Guest: Meet Dr. Phillip Frost: Billionaire CEO and the Healthcare Pioneer Behind OPKO Health $OPK Website: https://www.opko.com/ Ticker: $OPK His Wikipedia page: https://en.wikipedia.org/wiki/Phillip_Frost Bio: Dr. Frost has been the CEO and Chairman of OPKO since March 2007. Previously, Dr. Frost served at Teva Pharmaceutical industries, Limited (“TEVA”) as both Chairman of the Board and Vice Chairman. Dr. Frost served as Chairman of the Board of Directors and CEO of IVAX Corporation from 1987 until its acquisition by Teva in January 2006. He also served as Chairman for Key Pharmaceuticals, Ladenburg Thalmann Financial Services was a director of Continucare Corporation and Castle Brands, Inc. He was also a Governor and Co-Vice-Chairman of the American Stock Exchange. Dr. Frost is a past chairman and currently serves as a member of the Board of Trustees of the University of Miami, the Shanghai Institute for Advanced Immunochemical Studies in China, and as a Trustee of the Miami Jewish Home for the Aged and the Mount Sinai Medical Center. He also serves as a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science. He is a past member of the Board of Trustees of the Scripps Research Institute, the Board of regents of the Smithsonian Institution, and the Skolkovo Foundation Scientific Advisory Council in Russia. Dr. Frost is a director of Cocrystal Pharma Inc, a publicly traded biotechnology company developing new treatments for viral diseases. --- Support this podcast: https://podcasters.spotify.com/pod/show/smartmoneycircle/support

Just back from The Running Event in Austin where I was immersed in the world of running from shoes and gear to community and friends. The Running Event is a trade show catering to specialty retailers, running media and influencers with over 8,872 Verified attendees, where 336 brands from around the globe converged in one place to showcase their 2025 running shoes, apparel, tech, nutrition, hydration and gear.  In addition to the trade shows, many of the brands host group runs, panels, and events. High vibes in Austin Texas! Tune in here for some of my top takeaways for 2025 from running industry trends, shoe design innovation, and some cool shoes, gear and apparel dropping in the new year! During my 72 hour trip to Austin, I met up with over 20 brands, recorded 14 video convos, and went to a few fun events.   You can watch the convos and shoe chats on the Marni On The Move Podcast YouTube Channel  and the Sub 5 Series. Caught up with Adidas, Altra, Brooks, Craft, Hoka, Mizuno, Mount To Coast, New Balance, Nike, On, Teva, Salis, Suunto, Gorewear to get the inside scoop on whats up for 2025. CONNECT Marni On The Move Instagram, TikTok, LinkedIn, or YouTube` Marni Salup on Instagram and Spotify SUBSCRIBE TO OUR NEWSLETTER Sign up for our weekly newsletter, Do What Moves You, for Marni on the Move updates, exclusive offers, invites to events, and exciting news! SUPPORT THE PODCAST Leave us a review on Apple. It's easy, scroll through the episode list on your podcast app, click on five stars, click on leave a review, and share what you love about the conversations you're listening to. Tell your friends to what you love on social. Screenshot or share directly from our stories the episode you're listening to, tag us and the guests.

In this CME podcast, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the history of muscarinic receptor science in schizophrenia and how that informs the mechanisms of action of novel muscarinic-targeting drugs for this disorder. They also discuss the efficacy and safety of these drugs and provide practical strategies for prescribing xanomeline-trospium.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Discuss the history of muscarinic receptor science and the role of muscarinic receptors in schizophrenia treatment Differentiate novel and in-development muscarinic-targeting treatments for schizophrenia based on their unique mechanisms of action, efficacy, and tolerability data   Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: November 27, 2024*   Expiration: November 26, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-SCHIZ01  Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until November 26, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry and psychopharmacology — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Jonathan M. Meyer, MD Voluntary Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Consultant/Advisor: AbbVie, Alkermes, Bristol Myers Squibb, Intra-Cellular, Neurocrine, Sumitomo, Teva Speakers Bureau: AbbVie, Alkermes, Axsome, Bristol Myers Squibb, Intra-Cellular, Neurocrine, Teva The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Meghan M. Grady, BA, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an educational grant from Bristol Myers Squibb.

Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceutica

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good — MilliporeSigma expands ADC manufacturing  The bad — EU fines Teva The ugly — AZ exec under investigation

Thursday November 7, 2024 EC Fines Teva $502 Million

In this week's Parasha , Noach was commanded to bring into the Teva two of every kind of animal that existed in the world to keep it's species alive. The sefer Birkat David quotes from studies that were done investigating how many species exist in the world. It said there are 10 kosher animals, 5,300 non-kosher animals, 18,000 kinds of reptiles, 9,000 kinds of birds and hundreds of thousands of insects. As big as the teva was, it was mathematically impossible for all of those animals to have fit on it. Furthermore, Noah and his family were given the job of feeding those animals. Even if every one of them would have spent all of their 24 hour days feeding the animals, they still wouldn't even come close to reaching every animal each day. Moreover, where was all that food stored ?Just the elephant alone eats approximately 300 pounds of food a day. Obviously this must have been accomplished by way of a miracle from Hashem. If that's the case, the Ramban asks, why did Hashem instruct Noah to build such a big Teva ? Anyway, it wasn't going to fit everything. He answered, Hashem wanted the miracle to be minimized as much as possible. And then he added, this is the way of all miracles. Man has to do all he can. And then Hashem does the rest. This is how it is with everything we do in life. We go through the motions, doing what we can, and Hashem is the One who gets things done. With this knowledge, if a person ever runs into a situation where it doesn't seem possible for him to accomplish his goal, but he knows it's the right thing to do, his job is to proceed with it, and he can then leave the rest to Hashem. Rabbi Avraham Salem, a mohel in Israel, told the following story about himself. Some years back on a hot day in the month of Elul, he had many brit milas scheduled in Netanya and the surrounding areas. The second to last one of the day was scheduled for 7:00 PM in one location. And the last one was in a different location pretty far from there, with sunset being at 7:15. This meant the mohel would have less than ten minutes to get there and do that last brit milah . He had no other choice. That was the only possibility for him to get all of them done on that day. While he was driving to that last brit milah, he saw smoke coming from underneath his car, and he quickly pulled over. He saw one of his tires was completely flat. It was too late to first call a taxi. He made a tefila to Hashem, "Please help me get this Mila accomplished." It seemed impossible to get there and complete it before sunset. But this rabbi knew he had to put in the effort and Hashem would decide what happens. So he waved down the next car driving by and begged the driver to help him. The driver was apprehensive, not knowing who this man was. The rabbi already started thanking him and got into his car and told him, "Please just go. I assure you we are doing holy work. I'll explain on the road." It was about a five mile drive to the next place, and there was nine minutes to go until sunset. The rabbi told the driver who was not religious, "You are Hashem's messenger. I am trying to get a brit mila done by the end of the day. I'm going to say Tehilim now and you just drive" When they arrived at the address, the rabbi was afraid to look at his watch. The driver told him you still have more than four minutes to go. The rabbi ran into the shul and was able to finish the mila before sunset. When he came out, he told the driver, you have no idea how great of a mitzvah you just did. The driver then said, "My name is Shimon. And if I just did a great mitzvah and you are a rabbi, please give me a beracha that I should get married. I'm 45 and I'm still single. I'm so lonely." The rabbi then put his hands on Shimon's head and gave him a heartfelt beracha and concluded by saying, "B'ezrat Hashem, I will have the merit to circumcise your first born son." The rabbi concluded this story by saying it was just one year later when Shimon called him in tears telling him that he got married two months after that episode, and now they had their first baby boy and were hoping he could come do the brit milah. That day that the rabbi tried to do all of those brit milas it seemed like he hit a roadblock and wasn't going to be able to complete the mission. Yet he kept going, because he knew that he just had to make the efforts, and it will be Hashem who actually gets things done. Shabbat Shalom.

In this CME episode, Drs. Andrew Cutler and Roger McIntyre discuss the challenges and importance of diagnosing bipolar disorder as early as possible in the course of the illness. They also review strategies to achieve a correct diagnosis to provide the most efficacious and tolerable treatments available for bipolar disorder. Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Employ effective screening tools and assessment strategies to enhance diagnostic accuracy and achieve early diagnosis of bipolar disorder Develop patient-centered treatment plans that incorporate current evidence and individual patient factors Utilize shared decision-making approaches to optimize treatment outcomes for patients with bipolar disorder Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: November 01, 2024*   Expiration: October 31, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-BD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 31, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, New York Chief Medical Officer, Neuroscience Education Institute, Malvern, Pennsylvania Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, Ontario, Canada CEO, Braxia Scientific Corp, Toronto, Ontario, Canada Grant/Research: Canadian Institutes of Health Research, China National Natural Research Foundation, Global Alliance for Chronic Diseases, Milken Institute Consultant/Advisor: Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Alkermes, Inc.

*) Israel kills 26 Palestinians in air strikes across Gaza Israel continues with its deadly strikes on besieged Gaza. At least 26 Palestinians were killed and 47 wounded in Israeli air strikes on besieged Gaza. At least 16 Palestinians were killed and 30 wounded, including children, in strikes that targeted two houses north of the Nuseirat refugee camp in central Gaza. Horrific and heart-wrenching experiences continue to haunt Palestinians in Gaza. In one such incident, a Palestinian ambulance worker made a horrific discovery when the corpse on the stretcher that he was carrying turned out to be his mother, killed by an Israeli air strike in central besieged Gaza. *) Arab League calls for UN resolution against Israel's UNRWA ban Meanwhile, the Arab League called for the passage of a UN resolution opposing Israel's move to ban the UN Agency for Palestinian Refugees (UNRWA) from operating in the country. The meeting demanded that the representatives of Arab countries in New York coordinate with the ambassadors and representatives of friendly countries and the UN Secretariat to request a special session of the UN General Assembly, as it is the body that issued the decision to establish UNRWA, to discuss the repercussions of this serious Israeli law and to issue a UN resolution rejecting this illegal Israeli measure. However, Israel continued with its defiance and demolished the office of the UN Agency for Palestinian Refugees (UNRWA) in the Nur Shams refugee camp in the occupied West Bank. *) North Korea launches a new ballistic missile North Korea has launched a new intercontinental ballistic missile in its first test in almost a year of a weapon designed to threaten the US mainland and occurring days ahead of the US election. North Korean leader Kim Jong Un ordered the missile test and was at the launch site calling the launch “an appropriate military action” to show North Korea's ''resolve to respond to its enemies' moves'' that have threatened the North's safety. In response to this, South Korea announced new export controls on materials needed to produce solid-fuel missiles to restrict North Korea's ballistic missile development. *) Canada labels India as a cyber threat According to a report, a cyber defence agency charged with keeping foreign actors from infiltrating Canada's computer networks identified India as a cyber threat for the first time. According to its National Cyber Threat Assessment report the Indian state-sponsored cyber threat actors are likely to conduct cyber threat activity against Government of Canada networks for espionage. The report also said that as a breakdown in Canada-India relations continues, India will step up its cyber threats after Prime Minister Justin Trudeau linked New Delhi to serious crimes against Sikh Canadians. *) EU slaps $502M fine on the world's largest generic drugmaker Teva The EU has slapped the world's largest generic drugmaker Teva with a $502 million fine for "abusing its dominant position" to impede competition for its blockbuster multiple sclerosis medicine. The Israeli company said it would appeal against the EU's fine. The European Commission said that it found Teva artificially extended the patent protection of its drug Copaxone and "systematically spread misleading information about a competing product to hinder its market entry and uptake.

Is it possible for our actions to reshape not only our own destiny but the very essence of the natural world around us? This episode promises to illuminate that profound connection, as we explore the Beis Alevi's incredible insights on Parshas Noach. Drawing from ancient teachings and the interpretations of the Midrash and Rashi, we journey back to a time of great moral and physical corruption before the flood. Through these historical lessons, we aim to inspire a path of personal growth and spiritual enrichment in our own lives.We also investigate the immense weight of human free will, as explained by Rabbi Yoichanon in Masech to Sanhedrin 108, and the transformative effects our sins can have on animals and even the earth itself. By understanding this interconnectedness, we uncover the importance of building a spiritual sanctuary, akin to Noah's ark, to protect ourselves and future generations. Let us take a cue from Avram Avinu and Noah, and strive to construct our own "Teva," a holy environment where righteousness thrives amidst a world fraught with spiritual challenges. Join us on this enlightening journey as we prepare for a brighter future through the timeless wisdom of the Beis Alevi.Support the showJoin The Motivation Congregation WhatsApp community for daily motivational Torah content!Elevate your impact by becoming a TMC Emerald Donor! Your much-needed backing is crucial for our mission of disseminating the wisdom of the Torah. Join today for just $18.00 per month. (Use your maaser money!) https://buy.stripe.com/00g8xl5IT8dFcKc5ky------------------Check out our other Torah Podcasts and content! SUBSCRIBE to The Motivation Congregation Podcast for daily motivational Mussar! Listen on Spotify or 24six! Find all Torah talks and listen to featured episodes on our website, themotivationcongregation.org Questions or Comments? Please email me @ michaelbrooke97@gmail.com

Join Dr. Mario Castro and Prof. Vibeke Backer as they discuss airway remodeling and airway hyperresponsiveness and their impact in the lives of patients with severe asthma. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Mario Castro, MD, MPH, reports grants and research support from NIH, ALA, PCORI, AstraZeneca, Gala Therapeutics, Genentech, GSK, Novartis, Pulmatrix, Sanofi-Aventis, Shionogi, and Theravance. He receives consulting fees from Genentech, Teva, Sanofi-Aventis, Merck, Novartis, Arrowhead Pharmaceuticals, Allakos, Amgen, OM Pharma, Pfizer, Pioneering Medicines, and GSK. He receives payment for speaker bureau activities from Amgen, AstraZeneca, Genentech, Regeneron, Sanofi-Aventis, and Teva. He also receives stock options from Aer Therapeutics. Vibeke Backer, MD, has worked as an advisor, supervisor, and investigator of pharmaceutical studies and has received unrestricted grants from AstraZeneca, GSK, MSD & Schering Plough, ALK-Abelló, Nycomed, Chiesi, Novartis, Pharmaxis, Nigaard, Pfizer, Boehringer Ingelheim, Maribo Medico, Aerocrine, Teva, Sanofi, Regeneron, and BIRK NPC. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2401489 – 1.0 – 10/2024 MAT-US-2410093 v1.0 – P Expiration Date: 10/09/2026

In this CME episode, Dr. Andy Cutler interviews Dr. Leslie Citrome about the impact of tardive dyskinesia on patient-reported outcomes and quality of life. They discuss how to correctly assess and diagnose tardive dyskinesia, as well as effective management strategies that incorporate the individual needs of patients.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Understand the physical, psychological, social, and occupational impacts of tardive dyskinesia (TD) on patients Identify clinical tools and patient-reported outcome measures to assess the severity and impact of TD Formulate evidence-based treatment strategies for TD that enhance patient outcomes and quality of life Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: October 23, 2024*   Expiration: October 22, 2027 *NEI maintains a record of participation for six (6) years.   CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-TD   Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 22, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Delpor, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, Medavante-ProPhase, Merck, Mitsubishi-Tanabe Pharma, Neumora, Neurocrine, Neurelis, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumitomo/Sunovion, Supernus, Teva, University of Arizona, Vanda Speakers Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer, Reviva (options) The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Teva Pharmaceuticals.

In this new series on the Startup CPG Podcast, Daniel Scharff and Jamie Valenti-Jordan from Catapult Commercialization Services take callers who have had 'Ops Nightmares' that plague many brands. Joining them are Katherine Harvey, co-founder and CEO of Bare Bones Broth, who faced a bone broth launch disaster at Costco due to manufacturing and contamination issues; Brett Perrotta, co-founder and Chief Operating Officer of Chubby Snacks, who recounts his own ops nightmare involving production errors with a co-packer, underscoring the critical nature of founder involvement during initial production runs; and Brady DeLong, VP of Sales & Ops at Clean Age, who reveals chaos from a major inventory mix-up with Walmart.Teva from our sponsor, Crstl, provides expert advice on leveraging Electronic Data Interchange (EDI) for managing high order volumes, as well as for reducing chargebacks and driving revenues.Crstl: No-Code EDI for Modern BrandsTired of ops nightmares? Crstl is here to help! Whether you're new to retail or looking to migrate off your existing EDI platform, Crstl can onboard you to any retail trading partner for EDI in 2 weeks or less. Additionally, Crstl seamlessly integrates with all the platforms you need to run your business, such as Shopify, QBO, your ERP, your WMS, and more. Our best-in-class customer experience ensures you are never alone when challenges arise. Say goodbye to operational headaches and focus on what you do best—growing your brand!Learn more at https://www.crstl.so/demo and mention Startup CPG for 25% off your first annual subscription.Today's topics:Advice on Handling Ops NightmaresKatherine Harvey's Ops Nightmare at CostcoBrady DeLong's Operational Nightmare with WalmartBrett Perrotta's Operational Nightmare with a Co-PackerTeva's ( Crstl EDI ) DiscussionCommunication with BuyersHandling Freight ProblemsLegal and Insurance ConsiderationsDamage Control and TransparencyPlanning and Risk ManagementOperational and Product LossesCommon Business ChallengesPackaging and Labeling IssuesEpisode Links:Catapult Commercialization Services WebsiteJamie Valenti-Jordan LinkedInBare Bones Broth Website Katherine Harvey LinkedInClean Age WebsiteBrady DeLong LinkedInChubby Snacks WebsiteBrett Perrotta LinkedInDon't forget to leave a five-star review on Apple Podcasts or Spotify if you enjoyed this episode. For potential sponsorship opportunities or to join the Startup CPG community, visit http://www.startupcpg.com.Show Links:Transcripts of each episode are available on the Transistor platform that hosts our podcast here (click on the episode and toggle to “Transcript” at the top)Join the Startup CPG Slack community (20K+ members and growing!)Follow @startupcpgVisit host Daniel's Linkedin Questions or comments about the episode? Email Daniel at podcast@startupcpg.comEpisode music by Super Fantastics